Arcutis Biotherapeutics, Inc. (ARQT)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$35.1M
Cash & Equivalents
$2.2M
Quarterly Burn Rate
$3,470M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
ROFLUMILAST
ZORYVE |
APPROVED | Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis Eczema, Chronic Hand Eczema, Chronic Plaque Psoriasis, Eczema, Hidradenitis Suppurativa, ITCH, Non-segmental Vitiligo, Plaque Psoriasis, Psoriasis, Scalp Psoriasis, Seborrheic Dermatitis, Vitiligo |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-09-01 | Phase2 Readout | — |
| 2027-06-30 | Phase3 Readout | — |
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07105254 | An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patien... | PHASE2 | Recruiting | 20 |
| NCT07077902 | A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa | PHASE2 | Recruiting | 10 |
| NCT07453602 | Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 | PHASE1 | Recruiting | 125 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.